Table 1. Vaccination trial.

Group (n = 5)	Plasmid	Vaccination route*	Dose (µg)	C. psittaci challenge§
1	pMOMP	i.m.† + i.n.‡	100 + 100	Serovar A
2	pMOMP	i.m.	100	Serovar A
3	pMOMP	i.n.	100	Serovar A
4	pMOMP	Aerosol	100	Serovar A
5	pcDNA1 placebo	i.m. + i.n.	100 + 100	Serovar A
6	pMOMP	i.m. + i.n.	100 + 100	No
7	pMOMP+pIFN-γ	i.m.	100 + 100	Serovar A
8	pcDNA1 placebo+pCIneo placebo	i.m.	100 + 100	Serovar A
9	pcDNA1 placebo+pIFN-γ	i.m.	100 + 100	Serovar A
10	pMOMP+pIFN-γi.m.	100 + 100	No

^*Each group received a primary vaccination at time 0 followed by a booster vaccination 3 weeks later.

^†i.m., intramuscular.

^‡i.n. intranasal (DNA drops).

^§Challenge (10⁴ 50% tissue culture infective dose [TCID₅₀] Chlamydophila psittaci 84/55 serovar A) was administered by aerosol at 14 days after the second DNA inoculation.

IFN-γ, interferon-γ.